Introduction Postoperative cognitive dysfunction occurs frequently after coronary artery bypass grafting (CABG). The underlying mechanisms remain poorly understood, but neuroinflammation might play a pivotal role. We hypothesise that systemic inflammation induced by the surgical trauma could activate the innate immune (glial) cells of the brain. This could lead to an exaggerated neuroinflammatory cascade, resulting in neuronal dysfunction and loss of neuronal cells. Therefore, the aims of this study are to assess neuroinflammation in vivo presurgery and postsurgery in patients undergoing major cardiac surgery and investigate whether there is a relationship of neuroinflammation to cognitive outcomes, changes to brain structure and function, and systemic inflammation.
Methods and analysis The FOCUS study is a prospective, single-centre observational study, including 30 patients undergoing elective on-pump CABG. Translocator protein (TSPO) positron emission tomography neuroimaging will be performed preoperatively and postoperatively using the second generation tracer 18F-DPA-714 to assess the neuroinflammatory response. In addition, a comprehensive cerebral MRI will be performed presurgery and postsurgery, in order to discover newly developed brain and vascular wall lesions. Up to 6 months postoperatively, serial extensive neurocognitive assessments will be performed and blood will be obtained to quantify systemic inflammatory responses and peripheral immune cell activation.
Ethics and dissemination Patients do not benefit directly from engaging in the study, but imaging neuroinflammation is considered safe and no side effects are expected. The study protocol obtained ethical approval by the Medical Research Ethics Committee region Arnhem-Nijmegen. This work will be published in peer-reviewed international medical journals and presented at medical conferences.
Trial registration number NCT04520802.
- cardiac surgery
- delirium & cognitive disorders
- nuclear medicine
- intensive & critical care
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Strengths and limitations of this study
This study is the first to examine in vivo neuroinflammation using translocator protein positron emission tomography neuroimaging both prior to and after cardiac surgery.
This study combines state of the art neuroimaging with longitudinal neuropsychological examinations and detailed immunological analyses.
Extensive neuropsychological examinations at four different time points enable us to detect even subtle changes in cognitive function.
This study is powered to detect the association between neuroinflammation and cognitive decline between baseline and hospital discharge, when the incidence of cognitive dysfunction is highest.
The power of this pilot study is inadequate to adjust for confounders.
Background and rationale
Coronary artery bypass grafting (CABG) has been associated with postoperative cerebral complications.1–4 These may occur directly postsurgery, like stroke or delirium, but can also have long-term sequelae such as postoperative cognitive dysfunction (POCD) and dementia. The incidence of POCD ranges from 20%–70% in the first week after surgery to 10%–40% in the following months but may increase again from one postoperative year onwards.1 5 Furthermore, patients have a 1.7-fold increased risk to develop new incident Alzheimer’s disease within 6 years after undergoing a CABG, compared with patients undergoing a percutaneous coronary intervention.6
Development of POCD is presumably related to perioperative brain hypoperfusion, cerebral microembolisation, haemodilution, hypercoagulability, cerebral hyperthermia and inadequate glucose homoeostasis.2 In addition, systemic inflammation is hypothesised as an important (and possibly treatable) factor for POCD pathogenesis.7–9 Cardiac surgery produces substantial systemic inflammation (reflected by leucocytosis and significant dysregulation of cytokines and other inflammatory mediators, affecting various physical processes) due to multiple stimuli such as sternotomy, extracorporeal circulation (ECC), associated transient endotoxaemia and aortic cross-clamping. Systemic inflammation can result in increased communication and signalling from the periphery to the brain.10 11 As a result, systemic inflammation may induce activation of the innate immune cells of the brain, the microglia and astrocytes, leading to a neuroinflammatory response.12 Animal models demonstrated that systemic administration of low-dose endotoxin even leads to long-term inflammatory reprogramming of microglia.13 Interestingly, research has shown that neuroinflammation is associated with cognitive dysfunction and neurodegenerative disease.14 15 Given these associations, we hypothesise that occurrence of POCD in patients undergoing CABG is mediated through the occurrence of neuroinflammation.
Positron emission tomography (PET) enables the imaging of glial activation in the central nervous system (CNS) using radiolabelled antagonists of translocator protein (TSPO).16 17 TSPO is mainly expressed as a transmembrane protein on mitochondria of microglia and astrocytes in the CNS.18 As TSPO expression is upregulated during neuroinflammatory processes, it makes a promising biomarker for imaging neuroinflammation.19 Up to now, TSPO neuroimaging has been applied in a wide variety of neurodegenerative and psychiatric conditions, showing associations between neuroinflammation and cognitive decline.20–22 Recently, first in vivo evidence of microglial activity in response to systemic inflammation has been shown in patients and healthy volunteers.23–26 However, human in vivo data on neuroinflammation in patients undergoing major cardiothoracic surgery are still lacking.
This study, therefore, aims to assess neuroinflammation presurgery and postsurgery in vivo in patients undergoing elective cardiac surgery. Given the presumed association between neuroinflammation and cognitive decline, quantifying the extent of neuroinflammation postsurgery and its relation to POCD will provide us with important insights for future (interventional) research.
Our primary objective is to assess whether neuroinflammation is more pronounced in patients with cognitive decline at hospital discharge after CABG surgery, compared to patients without cognitive decline.
To study the relation between the neuroinflammatory response and structural or functional changes to the brain postoperatively.
To study the relation between neuroinflammation and cognitive decline at 6 weeks and 6 months post-cardiac surgery.
To study the relation between neuroinflammation and postoperative delirium.
To study the relation between the perioperative systemic immune responses and neuroinflammation.
Methods and analysis
The FOCUS study (neuroinflammation in cognitive decline post-cardiac surgery) is a single-centre observational time-series design study investigating neuroinflammation, systemic inflammation and neuropsychological performance before-and-after CABG.
Study population and recruitment
All patients planned for elective CABG in an academic hospital in the Netherlands are screened. Table 1 presents the inclusion and exclusion criteria. The age criterion of 50 years or older is chosen for two reasons. First, older adults are more prone to subsequent long-term cognitive decline after cardiac surgery.27 28 Second, ageing is associated with a more exaggerated neuroinflammatory response following systemic inflammation.29
Screening and enrolment logs will be maintained for all patients. After written informed consent is obtained, a blood sample will be genotyped for rs6971 polymorphism using Taqman analysis on a 7500 Fast Real-Time PCR System (ThermoFisher Scientific, Waltham, USA). Low-affinity TSPO binding patients for the radiotracer used in PET imaging will be excluded from participation. In our predominantly Caucasian cohort, the estimated percentage of low affinity binders is below 10%.30
Patients’ demographics and information regarding their surgery indication, treatments, pre-existing comorbidity (Charlson Comorbidity Index),31 32 (re)admission, disease severity and mortality risk, length of mechanical ventilation, length of stay at the intensive care unit (ICU) and occurrence of delirium will be retrieved from the patients’ medical files. Table 2 shows an overview of events for this study, which will be defined subsequently in more detail.
Dynamic brain PET/CT scans will be obtained preoperatively and on the fourth (range: 3rd–7th) postoperative day. Dynamic imaging of the head will be performed for 60 min after intravenous injection of the radiolabelled TSPO antagonist 18F-DPA-714 (18-fluoride labeled N,N-diethyl-2-[4-(3-fluoroethoxy)phenyl]-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-acetamide), a second generation TSPO ligand. This generation of TSPO ligands outperforms the first generation TSPO tracer, isoquinoline carboxamide (11C-PK11195), on TSPO binding affinity and PET imaging properties, but requires polymorphism genotyping and stratifying according to binding affinity status.33 A dose of ~200 MBq of 18F-DPA-714 will be administered as a slow bolus injection during 40 s. Scans are obtained on a Siemens Biograph mCT hybrid PET/CT scanner (Siemens, Erlangen, Germany). A low-dose CT will be acquired for attenuation correction and anatomical reference. For pharmacokinetic analysis of the PET data arterial blood sampling will be used.
In addition, a 3 Tesla brain MRI (Siemens TIM TRIO, Erlangen, Germany) will be performed on the same days as the PET/CT scans. T1-weighted MR images will be obtained to co-register with the PET images for anatomical reference. Whole brain grey matter, as well as regions of interest (ROI), will be delineated using probabilistic brain region templates. The slice thickness will be 1 mm. Additionally, the following MRI sequences will be performed: T2-weighed, susceptibility weighted imaging (SWI), fluid-attenuated inversion recovery (FLAIR), diffusion tensor imaging (DTI), resting state functional MRI (fMRI), time of flight (TOF) MR angiogram of the circle of Willis and precontrast and postcontrast three-dimensional high-resolution T1-weighted SPACE sequence to visualise vessel wall abnormalities. In order to visualise cerebral vessel wall abnormalities, 0.1 mmol/kg gadobutrol (Gadovist) contrast agent will be administered intravenously. Details on MRI settings are provided in online supplemental appendix 1.
A senior neuroradiologist blinded to all other data will systematically quantify newly developed lesions postsurgery. This enables us to analyse the relationship between neuroinflammation, neuropsychological decline and cerebral lesion load. To evaluate changes in brain functional connectivity due to an acute immune response, a resting-state fMRI measurement is implemented comparing resting state connectivity in stress-related brain circuits presurgery and postsurgery.34 35 A previous study found positive associations between alterations in resting-state functional connectivity in the brain’s default mode network and global cognitive change after cardiac surgery,36 and the current study enables us to extend these findings by studying the relationship with (neuro)inflammation.
Blood samples will be obtained at baseline preoperatively (T0, concomitant with the PET-scan), intraoperatively at the stop of ECC (T1), 6 hours after stop ECC (T2) and 24 hours after incision (T3). The timing of blood draws is based on the peak of the systemic inflammatory response post-cardiac surgery, as shown in previous studies we performed in patients undergoing cardiac surgery.37 38 Additionally, blood samples will be collected concomitant with the second PET/CT-scan (T4) and 6 weeks postoperatively (T5) to explore to what extent the inflammatory response persists in time.
At all time points, common blood parameters will be measured, including haemoglobin, leucocyte and thrombocyte count, and circulating pro-inflammatory and anti-inflammatory cytokines (including tumour necrosis factor alpha (TNF-α), interleukin (IL)-6, IL-1β, IL-10, and IL-1 receptor antagonist (IL-1RA)) by using simultaneous Luminex assays. Blood will be centrifuged at 2000 g for 10 min and the plasma will be stored at −80°C for possible future additional testing in line with the objective of this protocol. In addition, danger-associated molecular patterns (including high mobility group box 1, heat shock protein-70, calgranulin-C (S100A12), calprotectin (S100A8/9), nuclear DNA and mitochondrial DNA) will be measured as reported previously,39 in plasma centrifuged for a second time at high speed (16 000 g).
Additionally, ex vivo production of cytokines by stimulated isolated peripheral blood mononuclear cells will be measured, including TNF-α, IL-6, IL-1β, monocyte chemoattractant protein-1 and IL-10. Flow cytometry analysis of whole blood will be performed as described previously,40 41 to study the inflammatory phenotype of the cells (including expression of human leucocyte antigen-DR, C-C chemokine receptor type 2, CD11b, CD14 and CD16).
Arterial blood samples will be taken immediately before the 18F-DPA-714 injection and during the PET-scan to measure the time course of radioactivity in plasma. In addition to this pharmacokinetic sampling, blood samples will be used to assess the ratio of 18F-DPA-714 and its metabolites in order to correct the arterial input function for metabolite formation.
A trained psychologist will perform neuropsychological assessments preoperatively (T0), at hospital discharge (T4), after 6 weeks (T5) and 6 months (T6) follow-up. These assessments are in line with the recommendation for neuropsychological research in cardiac surgery patients.42 Table 3 lists the full test battery used for the neuropsychological assessments as well as the self-report questionnaires. Tests were selected based on sensitivity to detect even subtle deterioration in cognitive performance, with a focus on the domains executive functioning, memory, speed of processing and language. We will use parallel versions of these tests to account for material-specific practice effects after repeated assessment.43
During hospitalisation, screening of delirium is standard of care. Confusion Assessment Method for the ICU44 or Delirium Observation Screening scores45 46 at the cardiothoracic ward will be performed three times a day. A dedicated senior delirium researcher or neurologist will validate the diagnosis of delirium, using DSM-5 (Diagnostic and Statistical Manual of Mental Disorders 5th edition) criteria for delirium.47
Perioperative care will be delivered according to the regular clinical protocol for CABG. This minimises the risk of potential confounders due to variability in medical management.
Pharmacokinetic modelling of dynamic PET data will be performed in PMOD software (PMOD Technologies, Zürich, Switzerland). Binding potential (BPND) and volume of distribution (VT) in several regions of interest (ROIs) will be determined using the 2-tissue compartmental model for each scan. Predefined ROIs include the frontal, temporal, parietal and occipital lobes, amygdala, hippocampus, thalamus, cerebellum and the brain stem.
For each patient, 18F-DPA-714 BPND will be measured in the ROI for baseline and post-surgery PET scans. Since BPND is proportional to the availability of TSPO binding sites in the brain, an increase in BPND reflects an increase in glial activation. In addition, we will measure VT which recently has been shown to mainly reflect changes in peripheral tracer binding during systemic inflammation, rather than changes in TSPO expression in the brain.25 (and unpublished data from our group) Therefore, both outcome measurements are required to validate these recent findings and assess glial activation accurately. Study investigators who analyse the cerebral imaging data will be blinded for inflammatory mediator results and cognitive outcomes.
No consensus about the definition of POCD has been achieved in the literature thus far.5 48 49 At all time points, neuropsychological tests of our patients will be compared with available normative data, adjusted for age and educational level, resulting in standardised z-scores. Overall domain z-scores will be calculated by averaging the z-scores of the individual tests within a specific domain. Calculation of test performance will be supervised by an experienced clinical neuropsychologist. Additionally, z-scores of each individual test will be clinically classified as either being within the normal range (0), below average (1) or impaired (2), compared with the aforementioned normative data. ‘Normal performance’ is defined as performance above −1 SD from the normative mean. ‘Below average’ as between −1 SD and −1.65 SD from the normative mean (the lowest 16% of the normal population) and ‘impaired’ as below −1.65 SD from the normative mean (the lowest 5% of the normal population).50 51 Thus, an overall weighted performance score will be calculated for all five cognitive domains. A cognitive domain will be clinically classified as impaired when the average weighted score of all tests within the domain is >1. We will define the presence of POCD when 1) patients are impaired in one or more domains at hospital discharge, compared with baseline, or 2) when the overall weighted performance score deteriorated (from classification score 0 or 1 to 1 or 2, respectively) in more than one domain at hospital discharge compared with baseline. Accordingly, all patients will be dichotomised into two groups: with or without POCD at hospital discharge.
The percentage change in TSPO expression (postoperative vs preoperative) will be calculated and reported as mean±SE of the mean (SEM) if normally distributed. This value can be compared using unpaired t-tests between both groups with Bonferroni post hoc correction, and additionally, linear mixed models will be performed with the presence of POCD and brain region modelled as fixed effects, and subject ID as random effect. Additionally, the (change in) mean of the cognitive domain scores is analysed as continuous dependent outcome, with (change in) TSPO expression and (change in) systemic inflammatory markers as predictors in multiple linear regression models. Age, sex, Clinical Frailty Scale, Charlson Comorbidity Index, Hospital Anxiety and Depression Scale and the RAND-36 item health survey at inclusion can be included as covariates. Multiple logistic regression analysis is performed to correct for possible confounders such as newly developed structural brain lesions on MRI.
The trajectory of systemic inflammatory parameters and differences in time points will be measured with repeated measures one-way analysis of variance or linear mixed models in case of missings. In addition, correlations between systemic inflammatory markers and TSPO expression will be studied using Pearson for parametric or Spearman for non-parametric data. Unpaired t-tests will be applied to compare TSPO expression between patients with and without a delirious episode during hospital admission.
All MRI images will be evaluated without prior notice of any clinical parameter. White matter lesions are defined as hyperintense lesions on FLAIR MRI without corresponding cerebrospinal fluid like hypo-intense lesions on the T1-weighted image. Lacunar infarcts are defined as hypointense areas >2 mm and ≤15 mm on FLAIR and T1.52 Territorial infarcts are defined as hyperintense lesions on FLAIR, and hypointense lesions on T1 image.52 And finally, microbleeds are defined as small, homogenous, round foci of low signal intensity on T2* weighted images of <10 mm in diameter.53
Analyses of functional and structural brain images will be performed using FSL (FMRIB’s Software Library, Oxford, UK).54 After preprocessing and denoising, subject-wise spatial maps of with-in network brain connectivity of the salience, executive control and default mode networks will be compared with non-parametric tests for mean differences. Vascular wall enhancement will be compared between the preoperative and postoperative assessments with paired t-tests or the Wilcoxon signed rank test if the data are non-parametric.
Descriptive statistics will be performed using IBM-SPSS software, version 25. Mean (±SEM) or median (IQR) will be presented depending on the distribution of the data. Alpha will be set at 0.05 throughout.
After the first five patients we will schedule a technical interim analysis to establish whether a tissue reference model is a reliable, non-invasive method for pharmacokinetic analysis of TSPO neuroimaging during systemic inflammation-induced neuroinflammation. If this or other (mathematical) methods can be reliably validated in our cohort, there will be no longer need for arterial blood sampling.
Sample size calculation
No data on the degree of glial activation after systemic inflammatory responses in post-cardiac surgery patients are available. Research on cognitive dysfunction after cardiac surgery estimates a prevalence of approximately 50% at hospital discharge.1 5 48 Therefore, we will define two groups based on the presence or absence of cognitive dysfunction at hospital discharge.
Previous studies in dementia patients observed a 15%–35% higher PET tracer uptake in patients with cognitive impairment compared with healthy controls, with an SD of 30%.55 56 Therefore, we assume that patients with cognitive dysfunction at hospital discharge after cardiac surgery will have a 30% higher delta tracer uptake compared with patients without cognitive decline. To assess a 30% higher delta tracer uptake in patients with cognitive dysfunction, an unpaired two-sample t-test results in 13 patients per group with a power of 80% and a one-sided alpha of 0.05. In order to account for lower increments we will include 15 patients per group resulting in a power of 85% with an alpha of 0.05 to differentiate an increase of 30% in delta tracer uptake. Consequently, we will include a total of 30 patients, assuming that 50% will have cognitive decline at hospital discharge. The investigator can decide to withdraw a subject from the study for (1) urgent medical reasons or (2) if a protocol violation occurs or (3) if the subject is lost to follow-up. Replacement of individuals will not be necessary in this observational cohort once both PET scans are performed (ie, primary objective has been met).
Sample size calculations were conducted for the primary objective solely, considering cognitive decline at hospital discharge. Assessment of long-term cognitive outcomes (up to 6 months) together with assessment of our secondary outcomes has been set up in an exploratory setting. The data of this study will be important to calculate the power and feasibility of a subsequent prospective project focused on long-term outcomes.
Interim analysis with futility stop
An interim analysis will be performed after the first 15 subjects to validate that CABG surgery indeed induces a neuroinflammatory response, which will be assessed by TSPO PET imaging. An independent data safety and monitoring board (DSMB), composed by two clinical experts in the field of nuclear medicine and neurology, and a biostatistician, will analyse whether increased PET tracer uptake is observed after CABG surgery compared with the preoperative baseline tracer uptake. If no trend towards a significant difference (p>0.10) will be observed, the inclusion will be stopped to prevent futility. Furthermore an adaptive power analysis will be performed by the unblinded statistician DSMB member during the interim analysis to determine whether the study is underpowered to fulfil the primary objective, and whether the sample size should be adapted. The pooled SD of the delta PET tracer uptake will be calculated from the first 15 patients of which approximately 50% have cognitive disorders at hospital discharge. Using this pooled SD the sample size calculation will be performed again. If the ratio between this new sample size and the original is greater than 1, the sample size will be adapted if deemed feasible. The investigators will remain blinded for cognitive outcomes until the end of the study.
The study started enrolling patients in March 2019. The estimated study enrolment completion date is anticipated in the beginning of 2022. Please note that this manuscript was finalised prior to the interim analyses.
Ethics and dissemination
The study is conducted according to the principles of the Declaration of Helsinki and in accordance with the Dutch Medical Research Involving Human Subjects Act (WMO) and Good Clinical Practice guidelines. The study obtained ethical approval by the Medical Research Ethics Committee (MREC) region Arnhem-Nijmegen (CMO 2016–2598). The study is registered in the ClinicalTrials.gov database (NCT04520802). The burden of the study protocol consists of two PET/CT-scans and two cerebral MRIs, additional blood sampling before, during and after surgery and four neuropsychological examinations, two during hospital admission and two follow-up visits during the first 6 months after hospital discharge.
Patient and public involvement statement
The hypothesis of this study was conceived with the help of patients through outpatient clinical follow-up after an ICU admission. Through patient experience of different long-term consequences, this study’s endpoints involves cognitive performance, psychological symptoms and quality of life. A patient member of the MREC judged the study protocol for feasibility, burden and understandability of patient information.
Data will be handled confidentially and pseudonymously. Study data will be deidentified and a secured subject identification code list will be kept and stored separately from the data. This observational study uses an electronic remote data capture system. All missing and ambiguous data will be queried. The investigator will permit study-related monitoring, audits and regulatory inspection at their site, providing access to source data/documents. In all cases, it remains the responsibility of the investigator to ensure that data are accurate. Coded data will be kept after closure of the study and can only be used for ancillary studies after strict approval of the principal investigator. Anonymised data can be shared with other organisations for academic research, consensus development or other projects aimed at advancement of knowledge in this area. Body materials consisting of blood will be preserved in a coded form for 10 years for possible follow-up studies. The MREC will be consulted before body material is used for follow-up research.
Public disclosure and publication policy
The results of this study will be published, regardless of whether these are positive, negative or inconclusive, in peer-reviewed international (open access) medical journals and presented at medical conferences. In addition, a summary of the results of this study will be published on the website of the funding agency The Netherlands Organisation for Health Research and Development (ZonMw).
Relevance of findings
Cerebral dysfunction after cardiac surgery occurs frequently and may severely affect patients’ daily lives. Due to the lack of research data within this area, the pathophysiology of cerebral dysfunction postsurgery is unknown. Therefore, there are currently no interventions available to prevent or treat this deterioration. The FOCUS study will quantify glial activation, which is suggested to be important in this pathophysiology, and relate this to cognition, structural and functional changes to the brain and systemic inflammation. This adds to previous and ongoing observational work perioperatively combining blood and cerebrospinal fluid parameters with MR neuroimaging, cognition and electroencephalogram recordings.57 58 Our study combines state of the art molecular and MR neuroimaging techniques, elaborates longitudinal neuropsychological examinations and comprehensive immunological laboratory tests. Objective neurocognitive examinations will be performed at four different time points, up to 6 months postoperatively, enabling us to detect even subtle changes in cognition. Better understanding of the pathogenesis of POCD could direct neuroscientists towards the development of targets for future interventions. This imaging paradigm could provide an approach to examine the efficacy of such interventions in clinical studies.
In addition, the knowledge obtained with this study is of importance for patients and healthcare professionals as well. The participating patient will not directly benefit from study participation. However, they will be followed with regard to possible complaints in light of potential post-cardiac surgery cerebral dysfunction. This will increase the awareness of the participating patients and caregivers with respect to such complaints. This might benefit the patient and caregivers as it will decrease uncertainty about the nature of the complaints when they occur. Furthermore, this study searches for a biological explanation for post-surgery cerebral complaints which are often not understood or classified as functional.
Several limitations need to be addressed. First, as this study is powered at cognitive decline at hospital discharge, it is not powered to study the association between glial activation and cognitive decline after 6 months. The second limitation concerns the arterial sampling during the dynamic PET-scans. Automated arterial sampling, which is frequently used in other studies using outpatient clinic patients, leads to a significant loss of blood per scan. Loss of such an amount of blood in cardiac surgery patients is not preferable as it could result in a significant health risk for these critically ill patients. Therefore we will sample manually, which reduces blood volume loss. Manual sampling results in less sampling points and could therefore lead to a slightly less accurate plasma activity curve. Unfortunately, TSPO expression is not specific to microglia and astrocytes, and the measured PET signal can be affected by recruitment of peripheral monocytes to the brain, adherence of circulating leucocytes to the vascular epithelium, or TSPO expression in neurons or vascular endothelial cells. Finally, the power of this pilot study is inadequate to allow adjustment for all potential confounding factors.
Imaging neuroinflammation as proposed is safe, as corroborated by existing human and animal data. In addition, imaging neuroinflammation could lead to potential prognostic and interventional targets that could revolutionise healthcare for this large group of patients.
The authors are very grateful for the help of our colleagues at the department of Radiology and Nuclear Medicine, especially Gerben Franssen, Desirée Bos, Peter Laverman, Jurrian Butter, Peter Kok, Maichel van Riel, Michel de Groot, Marijke Hogenkamp and Judith Thijssen. In addition, we wish to thank Petra Budde, Jacqueline Blaauwbroek and Tanja Derks from the cardiothoracic planning office, for their help and flexibility in scheduling study patients. Assistance provided by the psychologists Chiara Fasotti, Claudette van Roij, Maud van Dorst and Lizzy van der Horst in performing the neuropsychological examinations was greatly appreciated. Furthermore we wish to thank Jelle Gerretsen and Matthijs Kox from the Intensive Care Research Unit for their input in the immunological assays in this study. Finally, this study could not be conducted without the help of the cardiothoracic surgeons, anaesthesiologists, intensivists and ICU nurses.
AMPvT and HBD are joint first authors.
Twitter @ICresearch_Rumc, @WilsonF_Abdo
Contributors WFA conceived the study idea. AMPvT and WFA developed the study design to which JvT, WWL, H-JD, NPR, FJAM, RPCK, NK, JGvdH, PP and MR contributed. AMPvT and HBD drafted the manuscript. All authors were involved in the editing of the manuscript and read and approved the final manuscript.
Funding WFA and this study were supported by a research grant from the Netherlands Organisation for Health Research and Development (ZonMW Clinical Fellowship grant 90715610).
Disclaimer This funding agency had no role in the concept, design or writing of this study.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.